Wall Street analyst estimates
Wall Street analysts estimate that DaVita (DVA) will report a 25.3% decline in revenues to $11.6 billion in 2018 compared to $15.5 billion in 2017. Its adjusted EPS is estimated at $4 in 2018 compared to $3.32 in 2017. Analysts estimate that its net adjusted income will increase to $693.4 million in 2018 compared to $634.9 million in 2017.
The above chart compares the changes in analyst recommendations for DaVita since January 2018.
DaVita stock has risen nearly 18.7% in the last 12 months but has fallen 2% in 2018 year-to-date. Analysts estimate that the stock could increase 13.6% over the next 12 months. Wall Street analysts are estimating a 12-month target price of $80.44 per share compared to $70.78 on September 14.
As of September 17, there are ten analysts tracking DaVita. Five of them have recommended a “strong buy” for the stock, and five have recommended a “hold.” None of them have recommended a “sell.” The consensus rating for DaVita is 2.0, which represents a “strong buy” for long-term growth investors and value investors. The changes in analysts’ estimates and recommendations are based on changing trends in the stock and the company’s performance.
The Invesco S&P 500 Equal Weight Health Care ETF (RYH) holds 1.4% of its total investments in DaVita (DVA), 1.6% in UnitedHealth Group (UNH), 1.6% in Becton Dickinson & Co. (BDX), and 1.7% in CVS Health (CVS).